X4 Pharmaceuticals to Participate at the Virtual B. Riley Oncology Institutional Investor Conference

Rhea-AI Summary

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) will participate in the B. Riley Oncology Institutional Investor Conference on January 20, 2021, at 11:00 AM ET. The event includes a fireside chat and one-on-one investor meetings. Due to audience limitations, advance registration is required. An archived webcast will be available on the X4 Pharmaceuticals website for 90 days post-event. The company focuses on developing therapies targeting CXCR4 pathway dysfunction, with its lead candidate mavorixafor currently in Phase 3 and Phase 1b clinical trials for various conditions.

BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the B. Riley Oncology Institutional Investor Conference on Wednesday, January 20, 2021, at 11:00 am Eastern Time, and conduct one-on-one investor meetings around the event.

Details are as follows:
Conference: Virtual B. Riley Oncology Institutional Investor Conference
Date: Wednesday, January 20, 2021
Time: 11:00 AM ET

B. Riley is limiting the live audience to attendees who register in advance.  An archived webcast of the event will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com, following the live fireside chat.  The event will remain archived on the X4 Pharmaceuticals’ website for approximately 90 days.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenstrom macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is developing additional product candidates. For more information, please visit www.x4pharma.com.

Investors and Media: 
Daniel Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Mónica Rouco Molina
Senior Account Executive
LifeSci Communications
mroucomolina@lifescicomms.com

FAQ

What event is X4 Pharmaceuticals participating in on January 20, 2021?

X4 Pharmaceuticals will participate in the B. Riley Oncology Institutional Investor Conference, featuring a fireside chat and one-on-one investor meetings.

What time will X4 Pharmaceuticals' fireside chat occur?

The fireside chat is scheduled for January 20, 2021, at 11:00 AM Eastern Time.

Is there a way to access X4 Pharmaceuticals' conference presentation after the event?

Yes, an archived webcast of the event will be available on the X4 Pharmaceuticals website for approximately 90 days after the conference.

What is the focus of X4 Pharmaceuticals' research and development?

X4 Pharmaceuticals focuses on discovering and developing therapies for diseases caused by dysfunction of the CXCR4 pathway, particularly rare diseases.

What is the status of X4 Pharmaceuticals' lead drug candidate?

X4's lead candidate, mavorixafor, is currently being evaluated in a global Phase 3 trial for WHIM syndrome and in Phase 1b trials for other conditions.